A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
NCT05205629
·
clinicaltrials.gov ↗
UNKNOWN
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Donafenib
Interventions
DRUG:
Donafenib combined with TACE
Sponsor
Shanghai Zhongshan Hospital